| Compound | Tirzepatide |
| Strength | 5mg, 10mg, 20mg, 30mg |
| Size_value | 5, 10, 20, 30 |
| Size_unit | mg |
| Vial_count | 1 |
| Purity_claim | ≥99% |
| Format | lyophilized vial |
5Mg:
| Quantity | Discount | Price |
| 5 – 8 | 5% | $56.05 |
| 9 + | 10% | $53.10 |
$79.00 – $325.00Price range: $79.00 through $325.00
Tirzepatide is a novel, synthetic linear peptide consisting of 39 amino acids. It represents the first class of “Twincretins” or dual-agonists. Structurally, it is based on the native GIP (Glucose-dependent Insulinotropic Polypeptide) sequence, but modified to simultaneously bind with high affinity to both the GIP receptor and the GLP-1 receptor.
This dual mechanism distinguishes Tirzepatide from single-agonists like Semaglutide. Research indicates that while GLP-1 activation drives satiety and slows gastric emptying, the addition of GIP activation enhances insulin sensitivity and lipid metabolism in adipose tissue. This synergistic approach is investigated for its potential to produce metabolic outcomes (weight reduction and glycemic control) that statistically exceed those of GLP-1 mono-therapies.
Key Research Applications
Superior Metabolic Regulation: Tirzepatide is the current benchmark for efficacy in metabolic research. Clinical data (SURMOUNT trials) demonstrated that the co-activation of GIP and GLP-1 receptors resulted in weight reduction of up to 20.9% in test subjects, significantly outperforming Semaglutide in head-to-head comparisons.
Adipose Tissue & Lipid Handling: The GIP component is specifically researched for its role in “buffering” dietary fats. Studies suggest that Tirzepatide improves the ability of white adipose tissue to store lipids safely (preventing ectopic fat deposition in the liver) while simultaneously promoting systemic insulin sensitivity.
Glycemic Control: By targeting two incretin pathways, Tirzepatide is investigated for its robust ability to lower HbA1c levels. It enhances first- and second-phase insulin secretion in response to glucose while suppressing glucagon, creating a more comprehensive glucose-lowering effect than targeting GLP-1 alone.
⚠️ FOR RESEARCH PURPOSES ONLY This product is intended for laboratory research and development use only. It is not intended for human consumption, diagnostic, or therapeutic use. Handle with care and adhere to all laboratory safety protocols.
| Compound | Tirzepatide |
|---|---|
| Strength | 5mg, 10mg, 20mg, 30mg |
| Size_value | 5, 10, 20, 30 |
| Size_unit | mg |
| Vial_count | 1 |
| Purity_claim | ≥99% |
| Format | lyophilized vial |
Reviews
There are no reviews yet.